Recent Advances in Anticancer Copper Compounds

Author:

Kellett Andrew1,Molphy Zara1,McKee Vickie12,Slator Creina1

Affiliation:

1. School of Chemical Sciences and National Institute for Cellular Biotechnology, Dublin City University Glasnevin Dublin 9 Ireland andrew.kellett@dcu.ie

2. Department of Physics, Chemistry and Pharmacy, University of Southern Denmark Campusvej 55 5230 Odense M Denmark

Abstract

There have been significant advances in the discovery of developmental copper complexes for the treatment of human cancer. The enzyme-active sites of several copper-containing enzymes suggest a starting point for metallodrug development and successful strategies have, so far, employed phenanthroline or bipyridine ligands to supply two pyridyl donors (modelling histidine residues) along with other oxygen or nitrogen donor ligands that tune specific properties. Suitably designed copper(ii) metallodrugs can generate reactive oxygen species (ROS) and reactive nitrogen species (RNS) that overwhelm innate cellular antioxidant defences to trigger oxidative damage and cell death. Recently, several complexes of this class were screened by the National Cancer Institute's (NCI) Developmental Therapeutics Program (DTP). The 60-cancer cell line screening results indicate copper(ii) metallodrug leads have unique activity and alternative mechanisms to clinically established anticancer agents such as cisplatin and bleomycin. Although DNA is a valid cellular target, mechanistic evidence suggests cell death is triggered by metal-catalysed pro-apoptotic ROS and RNS that damage cytoplasmic, mitochondrial, and genome function. In addition to copper complexes screened within the DTP, a number of other structurally relevant compounds are described, along with mechanistic aspects of their chemotherapeutic activity.

Publisher

The Royal Society of Chemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.7亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3